Unit
Immunity and Cancer (U932)
Thematic areas of research:
Image
To top
Unit
ANA-MARIA LENNON / OLIVIER LANTZ
Immunity and Cancer (U932)
Created in 2005, the INSERM U932 Unit is composed of 10 teams, spread over two buildings (Hôpital Curie and Constant-Burg building, rue Lhomond), with a total of about 120 people.
Teams
Key figures
334
publication since 2017
6
ERC since 2008
3
start-ups
Key publications
All publications
-
-
-
-
Constitutive Siglec-1 expression confers susceptibility to HIV-1 infection of human dendritic cell precursorsProceedings of the National Academy of Sciences
-
-
Rab6-dependent retrograde traffic of LAT controls immune synapse formation and T cell activationJournal of Experimental Medicine
-
-
News
All news
-
Manger des brocolis pour limiter les allergies cutanéesLa sévérité des allergies cutanées peut varier en fonction de nombreux facteurs environnementaux, et notamment du régime alimentaire. Cependant, jusqu’à présent, la contribution de nutriments spécifiques n’avait pas été bien documentée. Dans une nouvelle étude, des chercheurs et chercheuses de l’Inserm et de l’Institut Curie ont montré que l’absence dans l’alimentation de composés que l’on retrouve dans certains légumes, en particulier les brocolis et les choux, pouvait aggraver les allergies cutanées dans des modèles animaux.17/05/2023 -
Institut Curie - Institut Pasteur partnership: two joint projects to promote innovation and advancement of knowledgeImplementing their collaborative research strategy, Institut Curie and Institut Pasteur have raised the impressive amount of €600,000 to finance two research projects involving two teams from each organization. The MUCTOLIN project, looking at the role of tolerance induced by mucus during Listeria infection, and the TicTac project, which aims to study the effects of geometry on the healthy or cancerous status of a cell or on its development, were chosen.28/04/2023 -
Cryomicroscopy: the Research Center thinks bigThe brand new Glacios Cryo-TEM™ by Thermo Fischer was received in February at Institut Curie’s Research Center, This powerful cryo-electron microscope worth over 2 million euros will enable researchers to observe proteins at unprecedented resolution. A new opportunity to understand their function and the alterations responsible for diseases, particularly cancer.17/04/2023 -
Institut Curie’s latest progress at the AACR Annual Meeting 2023From April 14 to 19, 2023, in Orlando, USA, the international scientific and medical community comes together for the annual meeting of the American Association for Cancer Research, an opportunity for scientists from Institut Curie to present their findings in various fields of cancer research.17/04/2023 -
New data on the response of immune sentinels to HIV infectionAn article published in iScience on February 17, 2022, by the team of Philippe Benaroch, Myeloid cells and immunity, reveals how key sentinels of the immune system, namely human dendritic cells, may respond in two different ways to HIV-1 infection depending on the virus entry pathway.17/03/2023 -
Institut Curie certified as Integrated cancer research site for the third timeFollowing a call for applications launched in April 2022, Institut Curie had its integrated cancer research site project certified by France’s Institut national du cancer (Inca). Its goal is to better understand tumor recurrences in order to better prevent, detect and treat them.20/02/2023
Scientific events
All scientific events
30 Jun
2023
Seminar
11h-23h
Predictive models of stochasticity in cancer immunotherapy: from single lymphocytes to global inflammation
and back
to be completed soon
20 Jun
2023
Seminar
11h-23h
Understanding immune aging in mice and humans
Dr. Artyomov will present his work in immune aging where his laboratory using characterized immune aging in mouse tissues identifying GZMK+ CD8 T cells as uniform hallmark of aging. In parallel effort profiling of human circulating immune cells revealed existence of dedicated GZMK+ CD8 effector memory T cells in the peripheral blood that accumulate with age. We will discuss their transcripti
14 Jun
2023
Institutional seminar "Mayent - Rothschild"
11h-13h
Type I IFNs in health and disease: from trisomy 21 to cancer
Type I interferons (IFNs) activate intracellular antimicrobial programmes and influence the development of innate and adaptive immune responses. We will discuss our results by addressing the biology of IFN in Down syndrome (DS). This syndrome is the consequence of a chromosomal anomaly known as "trisomy 21" in which chromosome 21 is partially or totally tripled. The subunits that make up
14 Jun
2023
Institutional seminar "Mayent - Rothschild"
11h-23h
Lessons from COVID-19 vaccines: high dimensional analyisis of specific T and B cell immune response reveals distinct immunological signatures in 16 combinations of vaccines
The range of vaccines developed against SARS-CoV-2 gave a unique opportunity to study immunization across different platforms. In a single-center cohort with more than 400 volunteers, we analysed the humoral and cellular immune compartments following five COVID-19 vaccines spanning three technologies (adenoviral, mRNA, and inactivated-virus) administered in 16 combinations. Quantification of speci
6 Jun
2023
Seminar Immunology series
11h-23h
Definitional and characterisation of human tissue mononuclear phagocytes and their role in HIV transmission
Mononuclear phagocytes (MNP) consist of Langerhans cells, macrophages and dendritic cells (DC). They can become infected by HIV and transport the virus to its primary target cells (CD4 T cells) in association with their antigen presenting cell function.
We have revealed that the MNPs within anogenital tissues significantly differ to those in other parts of the body and we have defined thr
We have revealed that the MNPs within anogenital tissues significantly differ to those in other parts of the body and we have defined thr
Job offers
All job offers
-
Post-doctorat en Immunologie (vieillissement, macrophages, cancer du poumon) (H/F)Le Centre de recherche de l’Institut Curie
L'Institut Curie est un acteur majeur de la recherche et de la lutte contre le cancer. Il est constitué d'un hôpital et d'un Centre de recherche de plus de 1000 collaborateurs avec une forte représentativité internationale.
L’objectif du Centre de recherche de l’institut Curie est de développer la recherche fondamentale et d’utiliser les connaissances produites pour améliorer le diagnostic, le pronostic, la thérapeutique des cancers dans le cadre du continuum entre la recherche fondamentale et l’innovation au service du malade.
-
Postdoctoral Position in Immunology (aging, macrophages, lung cancer) (M/F)Institut Curie Research Center
Institut Curie is a major player in the research and fight against cancer. It consists of a Hospital group and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.
-
ENGINEER IN IMMUNOLOGY AND CELL BIOLOGY (M/F)The Curie Institute Research Center
The “Institut Curie” is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient. -
POSTDOCTORAL FELLOW IN IMMUNO-ONCOLOGY (M/F)The Curie Institute Research Center
The “Institut Curie” is a major player in the research and fight against cancer. It consists of a hospital and a Research Center of more than 1000 employees with a strong international representativeness.
The objective of the Curie Institute Research Center is to develop basic research and to use the knowledge produced to improve the diagnosis, prognosis, and therapeutics of cancers as part of the continuum between basic research and innovation serving the patient.